Navigation Links
Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
Date:12/7/2009

CORALVILLE, Iowa, Dec. 7 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the addition of new Board of Directors members, Dr. Francis Chen and Fritz Lin, M.D.

Dr. Francis Chen brings over 20 years of healthcare experience to his role as Board member of Vivakor, having held senior management positions at Becton-Dickinson, Baxter Healthcare and Hygeia Sciences/Tambrands among others. Dr. Chen earned his Ph.D. in immunology from Harvard University, and holds an M.S. and a B.S. in chemistry from Tufts University. Dr. Chen is Co-founder and Chairman of Pacific Advantage International, a marketing and sales support organization that assists U.S. and European information technology companies in establishing sales and distribution channels in the Asia-Pacific region. He is also Vice Chairman of W.I. Harper, a venture capital firm operating in the US, China and Taiwan, and serves on the board of Solar Power, Inc., Mail.com Media Corporation, LogicEase Solutions, and Stealth Peptides.

Fritz Lin, M.D., is a Professor of Clinical Pathology and Interim Chairman of the Department of Pathology and Laboratory Medicine at the University of California, Irvine School of Medicine. He is also the Director of Surgical Pathology & Cytopathology at the UCI Medical Center and is a member of the Chao Family Comprehensive Cancer Center. Dr. Lin is a highly respected clinician and is recognized as a Best Doctor in America by Best Doctors, Inc., an organization that bases its selection on survey results from other physicians. Dr. Lin's research interests center on the applications of principles of molecular biology, immunohistochemistry and cytometry, and he is playing a key role in the development of a human tumor tissue bank and various frozen tumor tissues for molecular and biological studies.

Vivakor CEO and Chief Scientific Officer, Tannin Fuja, Ph.D. shared his thoughts on these new members to the Vivakor team, "In the case of each of these gentlemen, Vivakor is quite fortunate to be able to draw on their experience and incredible wealth of knowledge in their respective fields. Dr. Lin is, literally, an icon in his field and his contribution to our scientific research cannot be underestimated. Dr. Chen brings the marriage of science and business acumen to the Board of Directors that will help guide its decisions well into the future. We are a stronger company with their presence."

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements which may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vivakor, Inc. Announces Stock Dividend
2. Vivakor Confirms Record Date of Stock Dividend
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
(Date:4/19/2017)... ... 2017 , ... A number of new instruments have recently emerged to accommodate ... Protein and Cell Analysis Education Webinar Series , will focus on advances in ... and future applications. , Many flow cytometers have unique capabilities and the Attune ...
(Date:4/19/2017)... ... 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical ... in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part ... webinars accessible to novices as well as experienced users, attendees will gain a ... coagulation screening tests. , Hemostasis testing quality is determined by preanalytical variables ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):